Memantine
1Provenance card
the boundary, as counts
Sources
4124 with DOI
27 strong · 10 moderate · 4 weak
Compilations
22026-05-09T11:13:49.359Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
31last ruled 2026-06-04
0 awaiting a ruling
Issued documents
42026-10-19T20:32:44.706Z
notice · info card · emergency
Searches
200 with no results
queries and counts on the build
Claims checked
6652 supported
52 supported · 14 not
Correspondence
0received
consent field ships in Phase 4
Edges
237
derivations recorded for this entity
Complete over 41 sources, 2 compilations, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/memantine/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-09-07srcMemantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial
- 2026-09-07srcMemantine for dementia
- 2026-09-07srcMemantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients
- 2026-09-07srcAmantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials
- 2026-09-07srcProtection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments
- 2026-09-07srcDistinct allosteric paths mediate a Ca2+-dependent increase in NMDA receptor sensitivity to open-channel blockers
- 2026-09-07srcMemantine: A look ahead. Insights into structure, syntheses, receptor binding mechanisms, drug hybrids and formulations, and potential repurposing
- 2026-09-07srcAdjunctive memantine for opioid use disorder treatment: A systematic review
- 2026-09-07srcPotency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive NMDA channel blocker memantine at human NMDA (GluN1/GluN2A) receptors
- 2026-09-07srcFluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer's disease
- 2026-09-07srcAdjunctive memantine for major mental disorders: A systematic review and meta-analysis
- 2026-09-07srcTargeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- 2026-09-07srcSafety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome
- 2026-09-07srcAlzheimer's disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography
- 2026-09-07srcMemantine inhibits calcium-permeable AMPA receptors
- 2026-09-07srcThe use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs: donepezil and memantine
- 2026-09-07srcConsensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
- 2026-09-07srcMemantine in moderate-to-severe Alzheimer's disease
- 2026-09-07srcIndistinguishable synaptic pharmacodynamics of the NMDA receptor channel blockers memantine and ketamine
- 2026-09-07srcMemantine augmentation of sertraline in the treatment of symptoms and executive function among patients with OCD
- 2026-09-07srcEffects on NMDA receptor blockade on feedforward and feedback processing
- 2026-09-07srcThe role of memantine in the treatment of psychiatric disorders other than the dementias
- 2026-09-07srcCombination Drug Therapy for the Management of Alzheimer's Disease
- 2026-09-07srcA causal role of the NMDA receptor in recurrent processing during perceptual integration
- 2026-09-07srcMemantine. Merz.
- 2026-09-07srcMorphine tolerance and reward but not expression of morphine dependence are inhibited by GCPII inhibitor 2-PMPA
- 2026-09-07srcDeterminants of trapping block of N-methyl-d-aspartate receptor channels
- 2026-09-07srcMemantine hydrochloride: pharmacological and clinical profile
- 2026-09-07srcFailures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine
- 2026-09-07srcThe molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism
- 2026-09-07srcInhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of NMDA receptors
- 2026-09-07srcPathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation
- 2026-09-07srcInflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders
- 2026-09-07srcA memantin HCL intoxication responsive to plasmapheresis therapy
- 2026-09-07srcAminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies
- 2026-09-07srcMemantine misuse and diversion practices: a netnographic analysis of users' experiences published online
- 2026-09-07srcMemantine for Huntington disease - NCT01458470 clinical trial
- 2026-09-07srcAdd-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis - NCT04789915
- 2026-09-07srcBasic information about memantine and its treatment of Alzheimer's disease and other clinical applications
- 2026-09-07srcMemantine for prevention of cognitive decline in breast cancer - NCT04033419
- 2026-09-07srcMemantine - StatPearls
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-09revisionRevision 1
- 2026-05-09genGeneration — pipeline-v5 · with 1 morepipeline-v5
- 2026-05-09rungeneration run
- 2026-04-28rungeneration run
The same entries, as forms: six forms.